GlassScriptPhysician profile
Lori Gonzales
NPI 1972870178
$5,151.76
in general payments reported to CMS, 2019-2025
19 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $273 · 2022: $712 · 2023: $1,810 · 2024: $695 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,201 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900.00 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,298.33 | 2023-2025 | Austedo, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $1,113.10 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $931.19 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $379.92 | 2021-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $298.89 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $281.39 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $248.77 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $196.54 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $134.76 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $55.22 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.14 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $35.24 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $24.01 | 2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $22.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.79 | 2024 | Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.48 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.57 | 2025 | Jardiance |
| Exact Sciences Corporation | $14.05 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $13.79 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.